DAGOBERTO CALLEGARO

(Fonte: Lattes)
Índice h a partir de 2011
20
Lattes
ResearcherID
Projetos de Pesquisa
Unidades Organizacionais
Instituto Central, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/45 - Laboratório de Fisiopatologia Neurocirúrgica, Hospital das Clínicas, Faculdade de Medicina
LIM/62 - Laboratório de Fisiopatologia Cirúrgica, Hospital das Clínicas, Faculdade de Medicina

Filtros

Limpar filtros

Configurações

Autor e Coautores FMUSP-HC Normalizados: MILENA SALES PITOMBEIRA × Autor e Coautores FMUSP-HC Normalizados: SAMIRA LUISA DOS APOSTOLOS PEREIRA × Categoria: original article × Assunto: Clinical Neurology ×

Resultados de Busca

Agora exibindo 1 - 2 de 2
  • article 47 Citação(ões) na Scopus
    Persistent MOG-IgG positivity is a predictor of recurrence in MOG-IgG-associated optic neuritis, encephalitis and myelitis
    (2019) OLIVEIRA, Luana Michelli; APOSTOLOS-PEREIRA, Samira Luisa; PITOMBEIRA, Milena Sales; TORRETTA, Pedro Henrique Bruel; CALLEGARO, Dagoberto; SATO, Douglas Kazutoshi
    Background: MOG-IgG-associated optic neuritis, encephalitis and myelitis (MONEM) is a recently recognized group of inflammatory central nervous system (CNS) disorders distinct from multiple sclerosis and neuromyelitis optica spectrum disorders. Limited data are available regarding the predictors of relapse in this condition. Objective: We aimed to evaluate the longitudinal serostatus of patients with MOG-IgG and to correlate serostatus with long-term clinical outcomes. Methods: Of 574 consecutive patients who presented with demyelinating inflammatory CNS disorders, we included 31 patients who were MOG-IgG-positive. Patients with MOG-IgG were followed up from 2011 to 2017 at the School of Medicine, University of SAo Paulo, Brazil. Results: Relapsing disease occurred in 23 out of 31 patients (74%), while 8 (26%) exhibited a monophasic course. All monophasic patients, as well as the majority of relapsing patients, became seronegative during clinical remission. Patients exhibiting disease activity in the last 2years were more likely to remain positive, with higher medium titres than those found in patients in clinical remission. Conclusion: MOG-IgG patients usually present with a relapsing course, and the risk of relapse was associated with longitudinally persistent MOG-IgG seropositivity. In contrast, patients who experienced a single attack became spontaneously seronegative for MOG-IgG during long-term follow-up.
  • article 14 Citação(ões) na Scopus
    Myelin imaging measures as predictors of cognitive impairment in MS patients: A hybrid PET-MRI study
    (2022) CAMPANHOLO, K. R.; PITOMBEIRA, M. S.; RIMKUS, C. M.; MENDES, M. F.; APOSTOLOS-PEREIRA, S. L.; BUSATTO FILHO, G.; CALLEGARO, D.; BUCHPIGUEL, C. A.; DURAN, F. L. S.; FARIA, D. De Paula
    Background: Cognitive impairment is one of the concerns of Multiple Sclerosis (MS) and has been related to myelin loss. Different neuroimaging methods have been used to quantify myelin and relate it to cognitive dysfunctions, among them Magnetization Transfer Ratio (MTR), Diffusion Tensor Imaging (DTI), and, more recently, Positron Emission Tomography (PET) with C-11-PIB. Objective: To investigate different myelin imaging modalities as predictors of cognitive dysfunction. Methods: Fifty-one MS patients and 24 healthy controls underwent clinical and neuropsychological assessment and MTR, DTI (Axial Diffusion-AD and Fractional Anisotropy-FA maps), and C-11-PIB PET images in a PET/MR hybrid system. Results: MTR and DTI(FA) differed in patients with or without cognitive impairment. There was an association of DTI(FA) and DTI(AD) with cognition and psychomotor speed for progressive MS, and of C-11-PIB uptake and MTR for relapsing-remitting MS. MTR in the Thalamus (beta=-0.51, p=0.021) and Corpus Callosum (beta=-0.24, p=0.033) were predictive of cognitive impairment. DTI-FA in the Caudate (beta=-26.93, p=0.006) presented abnormal predictive result. Conclusion: Lower myelin content by C-11-PIB uptake was associated with worse cognitive status. MTR was predictive of cognitive impairment in MS.